98 results on '"Rieder, Florian"'
Search Results
2. The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease.
3. Mo1784 HIGH-RESOLUTION IMPEDANCE PLANIMETRY CHARACTERIZES THE MECHANICAL FEATURES OF CROHN'S DISEASE STRICTURES – IMPLICATIONS FOR PATIENT STRATIFICATION.
4. Mo1763 POSTOPERATIVE RECURRENCE IN INFLAMMATORY BOWEL DISEASE ASSOCIATED PERMANENT END ILEOSTOMY: A SYSTEMATIC REVIEW.
5. Su1770 EFFECT OF RISANKIZUMAB ON EARLY SYMPTOMS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF THE INSPIRE INDUCTION STUDY.
6. Sa1881 MICROBIAL TRIMETHYLAMINE EXERTS PROFIBROTIC PROPERTIES IN IBD - IMPLICATIONS FOR NOVEL ANTI-FIBROTIC THERAPIES.
7. Sa1267 ESOPHAGEAL LUMINAL DIAMETER IS ASSOCIATED WITH DYSPHAGIA IN EOSINOPHILIC ESOPHAGITIS: IMPLICATIONS FOR ENDOSCOPIC DILATION THERAPY.
8. Sa1199 CONDENSINS ARE UPREGULATED IN CROHN'S DISEASE PATIENT ILEAL EPITHELIAL CELLS AND PROMOTE INTESTINAL PERMEABILITY.
9. 1142 INTEGRIN INHIBITION REDUCES PROFIBROTIC RESPONSES IN CROHN'S DISEASE (CD) HUMAN INTESTINAL MYOFIBROBLASTS IN VITRO AND AMELIORATES EXPERIMENTAL INTESTINAL FIBROSIS IN VIVO - A POTENTIAL NOVEL APPROACH TO CD STRICTURE THERAPY.
10. 1095 EXHALED BREATH ANALYSIS OF VOLATILE ORGANIC COMPOUNDS IS ASSOCIATED WITH LUMINAL DISEASE ACTIVITY IN PATIENTS WITH ULCERATIVE COLITIS.
11. 963 THE BREATH METABOLOME SIGNATURE IS LINKED WITH DIAGNOSIS OF EOSINOPHILIC ESOPHAGITIS: PILOT STUDY ASSESSING EXHALED VOLATILE ORGANIC COMPOUNDS.
12. 760 TRANSGLUTAMINASE 2 IS ELEVATED IN CROHN'S DISEASE ASSOCIATED STRICTURES AND EXERTS PROFIBROTIC ACTIVITIES IN MYOFIBROBLASTS AND EXPERIMENTAL INTESTINAL FIBROSIS.
13. 173 DUAL ACTIVATION OF GCGR/GLP1R SIGNALING AMELIORATES INTESTINAL FIBROSIS VIA METABOLIC REGULATION OF HISTONE H3K9 LACTYLATION IN EPITHELIAL CELLS.
14. Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel Disease.
15. An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials.
16. Not Hard to Swallow—Understanding Endothelial-Fibroblast Crosstalk in Eosinophilic Esophagitis.
17. Tu1718 A PHASE 1B STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS AND CLINICAL EFFICACY OF THE NUCLEOTIDEBINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS.
18. Tu1710 ADDITIONAL RISANKIZUMAB TREATMENT IS EFFECTIVE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO DID NOT ACHIEVE CDAI CLINICAL RESPONSE WITH THE INITIAL 12-WEEK INDUCTION TREATMENT: RESULTS FROM THE ADVANCE, MOTIVATE, AND...
19. Tu1256 USTEKINUMAB FOR THE TREATMENT OF SYMPTOMATIC SMALL BOWEL STRICTURING CROHN'S DISEASE - RESULTS FROM AN INTERNATIONAL MULTICENTER COHORT STUDY.
20. Tu1249 CROHN'S DISEASE INTESTINAL MUSCLE CELL DERIVED FIBRONECTIN PROMOTES PROLIFERATION OF INTESTINAL MUSCULARIS PROPRIA MUSCLE CELLS – A NOVEL LINK BETWEEN MUSCLE FIBROSIS AND PROLIFERATION IN STRICTURING CROHN'S DISEASE.
21. Tu1246 CROHN'S DISEASE STRICTURE MATRISOME ANALYSIS REVEALS THE ANTI-FIBROTIC ACTIVITY OF MILK-FAT GLOBULE-EPIDERMAL GROWTH FACTOR 8 (MFGE8).
22. Mo1735 EARLY HISTO-ENDOSCOPIC RESPONSE AT WEEK 12 PREDICTS CLINICAL OUTCOMES AT WEEK 52 WITH MIRIKIZUMAB IN ULCERATIVE COLITIS LUCENT TRIALS.
23. Mo1726 INTESTINAL ULTRASOUND OF FIBROSTENOTIC CROHN'S DISEASE CORRELATES WITH HISTOLOGY OF SURGICALLY RESECTED STRICTURES.
24. Cooling Down the Hot Potato: Anti-Interleukin 36 Therapy Prevents and Treats Experimental Intestinal Fibrosis.
25. ROCKing the Field of Intestinal Fibrosis or Between a ROCK and a Hard Place?
26. Mo1563: POST-OPERATIVE IMMUNOSUPPRESSIVE THERAPY FOLLOWING ILEAL POUCH ANAL ANASTOMOSIS CREATION: AN ASSESSMENT USING THE TRINETX COHORT.
27. Sa1591: INTRAABDOMINAL SEPTIC COMPLICATIONS AFTER ILEOCOLIC RESECTION INCREASES ENDOSCOPIC POSTOPERATIVE CROHN'S DISEASE RECURRENCE.
28. 720: EARLY INITIATION OF ANTI-TUMOR NECROSIS FACTOR THERAPY REDUCES POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE FOLLOWING ILEOCECAL RESECTION.
29. 719: POSTOPERATIVE CROHN'S DISEASE RECURRENCE RISK AND OPTIMAL BIOLOGIC TIMING AFTER TEMPORARY DIVERSION FOLLOWING ILEOCECAL RESECTION.
30. 587: EPIDEMIOLOGY AND RISK FACTORS ASSOCIATED WITH MALE SEXUAL DYSFUNCTION IN PATIENTS WITH ILEO-ANAL POUCH ANASTOMOSIS.
31. 456: CHRONOLOGIC AGE IS NOT ASSOCIATED WITH RISK OF POSTOPERATIVE RECURRENCE IN CROHN'S DISEASE.
32. 401: ANASTOMOTIC CONFIGURATION AND DIVERTING OSTOMY DOES NOT INCREASE THE RISK OF POSTOPERATIVE ANASTOMOTIC STRICTURES IN CROHN'S DISEASE.
33. Gastroesophageal Reflux Disease–Associated Esophagitis Induces Endogenous Cytokine Production Leading to Motor Abnormalities.
34. Development and Validation of a Novel Computed-Tomography Enterography Radiomic Approach for Characterization of Intestinal Fibrosis in Crohn's Disease.
35. Sa673 TWISTED POUCH SYNDROME - A DIFFICULT TO DIAGNOSE MECHANICAL COMPLICATION OF ILEAL POUCH-ANAL ANASTOMOSIS: OUTCOMES AFTER REDO POUCH PROCEDURES.
36. Su504 FLAGELLIN STIMULATION OF HUMAN INTESTINAL MYOFIBROBLASTS INDUCES CASPASE-1 ACTIVATION DRIVING FIBRONECTIN PRODUCTION – A NOVEL, TARGETABLE MECHANISM OF INTESTINAL FIBROSIS.
37. Su487 VEDOLIZUMAB AND USTEKINUMAB FOR THE TREATMENT OF SYMPTOMATIC SMALL BOWEL STRICTURING CROHN'S DISEASE - RESULTS FROM AN OBSERVATIONAL COHORT STUDY.
38. Su480 ACTIVATED INTESTINAL MUSCLE PROMOTES PREADIPOCYTE MIGRATION: A NOVEL MECHANISM OF CREEPING FAT FORMATION IN CROHN'S DISEASE.
39. Su479 FIBROSTENOTIC CROHN'S DISEASE MESENCHYMAL CELLS ARE RESISTANT TO THE ANTI-FIBROTIC ACTIVITY OF MILK FAT GLOBULE-EGF FACTOR 8 (MFGE8).
40. Sa580 REAL-WORLD EFFECTIVENESS AND SAFETY OF USTEKINUMAB AND VEDOLIZUMAB IN ELDERLY PATIENTS WITH CROHN'S DISEASE.
41. Sa545 STRICTURE LENGTH, DURATION AND OBSTRUCTIVE SYMPTOMS PREDIT TIME TO INTERVENTION IN CROHN'S DISEASE – A DERIVATION AND VALIDATION STUDY.
42. Sa546 WORSE OUTCOMES AND HIGHER COSTS OF CARE FOR PATIENTS WITH FIBROSTENOTIC CROHN'S DISEASE: A REAL-WORLD PROPENSITY-MATCHED ANALYSIS IN THE USA.
43. Sa496 CROHN'S DISEASE PREDISPOSES TO LIVER FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE. A PROPENSITY MATCHED ANALYSIS.
44. Sa462 ACCURACY OF IMAGING IN DETECTING POSTOPERATIVE CROHN'S DISEASE RECURRENCE.
45. Fr513 INCIDENCE OF INFECTIONS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH OZANIMOD AND RELATIONSHIP TO SIGNIFICANT LYMPHOPENIA: RESULTS FROM A POOLED SAFETY ANALYSIS.
46. 723 INFLAMMATORY BOWEL DISEASE HUMAN INTESTINAL MYOFIBROBLASTS DEPOSIT EXTRACELLULAR MATRIX WITH ENHANCED ADHESIVENESS FOR T-CELLS – A NOVEL MECHANISM FOR MAINTENANCE OF INTESTINAL INFLAMMATION.
47. 722 INCREASED LEVELS OF CADHERIN-11 EXPRESSION IN IBD PROMOTE FIBROBLAST ACTIVATION AND EXPERIMENTAL INTESTINAL FIBROSIS BUT NOT COLITIS ASSOCIATED CANCER.
48. 387 SEPTIN CYTOSCELETON IS A NOVEL REGULATOR OF INTESTINAL FIBROGENESIS.
49. 30 A NOVEL MECHANISM OF SPHINGOSINE-1-PHOSPHATE RECEPTOR (S1PR) MODULATORS IN INFLAMMATORY BOWEL DISEASES.
50. Collagenous Colitis Is Associated With HLA Signature and Shares Genetic Risks With Other Immune-Mediated Diseases.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.